TWA
MRKR icon

TCI Wealth Advisors’s Marker Therapeutics MRKR Stock Holding History

TCI Wealth Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-50
Closed -$1K – 1656
2019
Q4 		$1K Buy
50
+20
+67% +$728 ﹤0.01% 1384
2019
Q3 		$2K Buy
+30
New +$1.77K ﹤0.01% 1103

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
AAM
AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return
MAA
Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCI Wealth Advisors's MRKR Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Marker Therapeutics (MRKR) in Q2 2023, closing a stake of 10 shares — an estimated $8 sold.

TCI Wealth Advisors first reported a position in MRKR in Q1 2019 and held it in 17 quarters. The position peaked at $17K in Q2 2019. 29 funds tracked by Wall St. Rank hold MRKR as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Marker Therapeutics position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 10 Marker Therapeutics shares in Q2 2023, an estimated $8.
  • TCI Wealth Advisors first reported a position in Marker Therapeutics in Q1 2019 and held it in 17 quarters.
  • TCI Wealth Advisors's Marker Therapeutics position peaked at $17K in Q2 2019.
  • 29 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.